Supreme Petrochem Q1: consolidated PAT nearly triples YoY to ₹238 Cr on margin snap-back
PAT +189.54% YoY · revenue +22.3% · margins expanding
₹1,714.51 Cr
+22.3% YoY
₹237.57 Cr
+189.54% YoY
13.72%
+7.9pp YoY
₹12.62
Supreme Petrochem opened FY27 with a consolidated Q1 print that overran its own cautious setup: revenue rose 22.3% YoY to ₹1,714.5 Cr and net profit jumped to ₹237.6 Cr from ₹82.1 Cr a year ago — up ~189% — with EPS of ₹12.62 versus ₹4.35. The move is a margin story, not just a volume one: net margin widened to ~13.9% from 5.8% in Q1 FY26 and 10.4% last quarter, and operating margin expanded to roughly 19% from 8.3% a year earlier. The base was depressed (Q1 FY26 net profit had itself fallen ~34% YoY), so the optics flatter, but the sequential step-up (+6.8% revenue, +40.8% PAT QoQ) confirms the recovery is real and not purely a low-base effect. There are no exceptional items either this quarter or in the year-ago quarter, so the YoY growth is clean; only the QoQ base (Q4 FY26) carried a small ₹2.9 Cr labour-code charge.
Q1 FY-2027 vs prior quarters
The swing sits on the spread line — cost of materials consumed and stock-in-trade movements drove the gross-margin expansion, consistent with styrene/polystyrene spreads recovering off the raw-material volatility management flagged on the Q4 call. On that call management was explicitly cautious, said it could not predict Q1 given extreme feedstock volatility and non-OEM demand softness, and offered only a conditional 8–10% FY27 volume guidance; this print materially beats that near-term framing on profitability, though the filing gives no Q1 volume figure to confirm the demand-recovery leg. Alongside the results the Board approved a new 80,000 TPA polystyrene line at Amdoshi (₹325 Cr, internal accruals, on-stream by March 2029), which will lift polystyrene capacity to 3,80,000 TPA and extends the capex cycle management outlined earlier. The company remains debt-free.
The stock went into the print at ₹760.9, up 2.8% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Management provides a conditional full-year volume growth guidance of 8% to 10% for FY27, contingent on geopolitical stability and normal market conditions returning by the second quarter. The near-term outlook is highly uncertain due to extreme raw material price volatility and observed demand softness in non-OEM segm
— This quarter: beat
No published brokerage consensus for the quarter was found (the stock carries a 'Hold' screen rating), so the print can't be scored against a hard number; against management's own cautious guidance it is a clear beat on margins. Standalone and consolidated tell the same story — standalone PAT ₹236.3 Cr against consolidated ₹237.6 Cr — as the Xmold subsidiary is immaterial.
W1
Volume recovery: filing gives no Q1 volume; confirm on the July 29 concall whether the 8–10% FY27 volume guidance is holding (management said Q1 was unpredictable)
W2
Margin durability: net margin snapped to ~13.9% from 5.8% YoY on spread recovery — watch whether feedstock/styrene-spread volatility management flagged reverses it next quarter
W3
New 80,000 TPA polystyrene line (₹325 Cr) and ABS/EPS ramp — capex execution and utilisation against the ~₹250 Cr FY27 capex plan
Clean machine-readable statement in ₹ Lakhs, converted to ₹ Cr. Current quarter has NO exceptional item; year-ago (Q1 FY26) also none, so YoY is clean. Q4 FY26 (QoQ base) carried a small ₹2.9 Cr labour-code exceptional charge only. Consolidated adds tiny subsidiary Xmold Polymers; standalone vs consolidated differ <1%. Tax = current + deferred.
Margin mirage: +22% revenue, -24.5% volumes; exceptional profits are unsustainable
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 5/10
Grade B
Q1 numbers verified against delivered results (within 1-2%). FY27 volume guidance of 8-10% effectively cut (no reaffirmation post -24.5% Q1).
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 profitability surge is a commodity mirage: volumes collapsed 24.5% and non-OEM demand crashed 50%, offset entirely by transient global styrene-polymer margin widening (deltas USD 250-350 vs historical 150-200). Management explicitly warned this is an 'aberration' that will 'normalize' as geopolitical disruptions ease, implying rapid margin compression. Prior FY27 8-10% volume growth guidance has been abandoned with no replacement; refusal to project forward reflects high uncertainty. Near-term margin compression and export disruption risk outweigh long-term capex optionality.
₹1693 Cr
Revenue · +22.3% YoY₹236 Cr
Reported PAT · +189.5% YoYExpanding
Margins · vs guidance: OverstatedDid the claims hold up?
Revenue up 22% YoY, EBITDA margins 19.5%
METRevenue ₹1,693 Cr (+22% YoY), EBITDA 19.53% delivered; margins expanded but volumes declined 24.5%
Margin expansion from global deltas widening between styrene and products
METGPPS delta USD 200→300+ (50%+ rise), HIPS USD 275→400+ (45%+ rise); fully explains 188% EBITDA growth
Volume decline 24.5%, non-OEM demand down ~50%, exports down 90%
METVolumes 70,842 MT vs 93,853 MT prior year; non-OEM evaporated; exports minimal due to freight, supply constraints
Margins are aberration and will normalize as deltas compress
METManagement explicitly stated deltas are unsustainable; current GPPS 250-275 and HIPS 350 will revert; implies margin compression inevitable
Prior 8-10% FY27 volume growth guidance remains on track
MISSQ1 showed -24.5% volumes; management declined to reaffirm guidance, said Q1 not a benchmark; guidance effectively withdrawn
Earnings quality
What changed since the last call
Volume guidance withdrawn
DowngradePrior FY27 8-10% conditional growth guidance abandoned post -24.5% Q1 decline; mgmt declined to reaffirm or replace
Margin sustainability retracted
Downgrade19.5% EBITDA margin explicitly labeled 'aberration'; deltas will normalize; implies compression from current +300 bps to historical +150-200 bps
Export priority downgraded
DowngradeExports down 90% in Q1; mgmt shifted focus to domestic OEM; export recovery conditional on Red Sea/shipping normalization (timing uncertain)
Capex roadmap affirmed
NeutralEPS Phase 2 complete, new PS line approved Dec 2028; ₹450 Cr from internal accruals; unchanged from prior call
The Q&A
Analysts pressed hard on margin sustainability, forward guidance, and capex justification in weak volume environment. Management held firm on capex long-term rationale (India export growth, energy-efficient buildings, appliance manufacturing) but refused to quantify FY27 revenue/volume/margin guidance, citing fluid geopolitical situation. Responses heavily hedged; confidence signals weak.
Volume decline and demand — Nirav Jamudia, Anvil Wealth
AnsweredNon-OEM demand down ~50% due to high prices and gas supply constraints. OEM stable. Exports 90% down. Import duty exemption drove ~20k tons imports (vs normal ~87k). Situation unprecedented, not comparable to past cycles.
Profit driver sustainability — Disha Chamriya, Trinetra Asset Managers
AnsweredMargins entirely from global delta widening. Volumes down 25%. Deltas (GPPS USD 200→300+, HIPS USD 275→400+) are aberrations that will normalize. Margins dependent on global trends, not operational leverage.
FY27 volume and margin guidance — Aditya Khetan, SMIFS Equities
DodgedGiving guidance when situation fluid is very difficult. Non-OEMs stabilizing now. Uncertainty on exports, styrene availability, shipping, freight. Will take quarter by quarter. Q1 not benchmark for year.
Capex allocation and utilization — Sailesh Raja, 360 One Capital Market
AnsweredEPS done. Focusing on ABS line 2, XPS, compounds. PS line 5 approved last quarter. All capacities on board by March 2029. ₹900 Cr total capex from internal accruals. Asset turns 2x on full capacity.
Commodity pricing environment — Vipul Kumar Shah, Sumangal Investments
AnsweredCurrent CIF USD 1,300. Q1 range USD 1,350-1,400, peaked USD 1,500+. Current deltas GPPS USD 250-275, HIPS USD 350. Deltas peaked at 300+/400+, came down briefly in June peace accord, rebounded. Will normalize over time.
Industry growth justifying capex — Santosh Keshri, SKHKUF
AnsweredYes, at par with industry. EPS fragmented (many small players), we de-grew less. Polystyrene, industry de-grew same rate. Capex for long-term (2-2.5 yrs out), not temporary events. India export growth, cold chains, efficient buildings tailwinds. Board approved keeping these factors in view.
ABS compounds growth and market size — Aditya Khetan, SMIFS Equities
PartialNo ready numbers on ABS market size. Whatever capacity we build, demand exists to sell. Next 3-4 years should fully sell out new capacity. ABS did very well even in this weak quarter.
Customer response to price increases — Rohan Joshi, Individual
AnsweredNon-OEMs had price resistance, demand down. OEMs stable, demand same or better. Now non-OEMs have reconciled to price increases as global phenomenon. Demand from non-OEMs back into market.
Guidance
No quantified FY27 revenue guidance provided
LowManagement declined to project revenue citing fluid geopolitical situation; non-OEM recovery trajectory anecdotal
Current 19.5% EBITDA margin is unsustainable, will compress as deltas normalize
HighGlobal GPPS delta USD 250-275 (down from 300+), HIPS USD 350 (down from 400+); management explicitly said margins are aberration; historical deltas 150-200 bps imply revert to 12-15% EBITDA range
₹450 Cr capex: EPS by June 2027, PS line 5 by Dec 2028; ₹900 Cr total
HighBoard-approved; funded entirely from internal accruals; timelines firm; targeting 2x asset turns on full capacity across all segments
Risks the call surfaced
Supply chain disruption
HighAll three styrene plants in Middle East (major supplier) suspended operations. Strait of Hormuz disruptions cut cargo shipments. Company forced to source from distant suppliers at 20-30% freight premium. Red Sea shipping crisis ongoing.
Demand collapse
HighNon-OEM demand evaporated ~50% in Q1 due to price resistance and downstream gas supply constraints. Temporary import duty exemption (3.5 months) drove ~20k tons imports (~11% market share) vs normal ~87k tons annually, eroding domestic producer margins and share. Price resistance from non-OEM segment confirmed.
Margin compression
HighQ1 19.5% EBITDA margin entirely driven by exceptional global styrene-to-polystyrene spreads (GPPS +300 bps, HIPS +350 bps vs historical). Management explicitly warned this is an 'aberration' and deltas will 'normalize' as West Asia supply constraints ease. Historical deltas imply EBITDA margin revert to 12-15% range (400-500 bps compression).
Capex execution
Medium₹450 Cr capex (EPS June 2027, PS line 5 Dec 2028) assumes demand recovery over 2-2.5 year horizon. Industry and Supreme both de-grew 24.5% in Q1; capex predicated on structural India export growth and appliance manufacturing expansion (PLI scheme). Risk: demand recovery slower than expected, or macro deterioration, could leave new capacity underutilized.
Management
Score 6/10. Transparent on Q1 mechanics (price drivers, volume decline, margin sustainability) but heavily hedged on forward visibility. Explicitly warned margins are temporary/aberrations. Refused to quantify FY27 guidance (revenue, volume, margin) citing fluid situation. Capex roadmap and long-term strategy communicated clearly. FY26 guidance track record solid. FY27 8-10% volume growth guidance effectively abandoned after -24.5% Q1 decline (major miss). Capex projects on track (EPS Phase 2 complete). No new guidance provided to benchmark future execution.
1 · Q2 FY27 (Oct 26)
Non-OEM demand recovery and margin stabilization as geopolitical tensions ease
2 · June 2027
EPS Phase 2 + wide-width board 150k m³ line commissioned; compounding capacity 50k→80k tons
3 · Q2-Q4 FY27
Global styrene-polystyrene deltas revert to historical levels; margin compression likely
Near-term margin compression and export disruption risk outweigh long-term capex optionality.